Humacyte

Humacyte

生物技术研究

Durham,NC 11,288 位关注者

Our vision is to be the global leader in engineering regenerative medicine products to save and improve patient lives.

关于我们

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

网站
https://www.humacyte.com
所属行业
生物技术研究
规模
51-200 人
总部
Durham,NC
类型
上市公司
创立
2004
领域
Regenerative Medicine

地点

  • 主要

    2525 E NC Highway 54

    2525 E Hwy 54

    US,NC,Durham,27713

    获取路线

Humacyte员工

动态

相似主页

查看职位

融资

Humacyte 共 12 轮

上一轮

上市后股权

US$15,000,000.00

Crunchbase 上查看更多信息